In this video, Stefania Bramanti, MD, Humanitas Research Hospital, Rozzano, Italy, briefly describes the first case report of aseptic meningitis following CAR T-cell therapy. A 44-year-old male with late-stage mantle cell lymphoma (MCL) received CAR-T therapy with brexucabtagene autoleucel (brexu-cel) and was subsequently discharged from the hospital. However, at days 30 and 58 post-infusion, the patient presented with late-onset CAR T-cell-related neurotoxicity, which was eventually diagnosed as aseptic autoimmune meningitis. CAR T-cell re-expansion was observed both in the peripheral blood (PB) and cerebrospinal fluid (CSF). The patient’s neurological condition improved upon treatment with high-dose methylprednisolone and anakinra. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.